Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

<i>Background and Objectives</i>: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficien...

Descripción completa

Detalles Bibliográficos

Autores principales:	Shinsuke Suzuki, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, Takechiyo Yamada
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2021-10-01
Colección:	Medicina
Materias:	head and neck squamous cell carcinoma cetuximab paclitaxel immune checkpoint inhibitor chemotherapy
Acceso en línea:	https://www.mdpi.com/1648-9144/57/11/1151
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!